DH
DH.O
—
NASDAQ
Software
Definitive Healthcare Corp
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
123,3M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-93,1 %
ROE
-49,4 %
Net margin
-57,5 %
Debt / equity
0,59
Beta
—
52w range
—
Volume
1,9k
Day range
$0,85–$0,92
Prev close
$0,90
Open
$0,92
Next earnings
2026-07-28
Ex-dividend
—
TR 1Y
—
About
Definitive Healthcare Corp provides healthcare data and analytics software to support clinical, financial, and operational decision-making in the healthcare industry.
Business. Definitive Healthcare Corp (DH.O) is a software company operating within the Technology sector, specifically providing software and IT services. The firm generates revenue through a subscription model, with key performance indicators including annual recurring revenue and net revenue retention. No specific operating segments or geographic breakdowns are provided in the available data. The company is listed under the ticker DH.O.
Classification92 %
SectorTechnology
Business sectorSoftware & IT Services
IndustrySoftware
Generated · model-assisted
Sell-side consensus
HOLD12 analysts
3 buy8 hold1 sell
Avg 12m price target2,41
Analyst recommendations
12 analysts · consensus HoldBuy3
Hold8
Sell1
12-month price target
2,41
Consensus of sell-side coverage.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,2 %+1,6 %+2,4 %
Energy+1,2 %+5,3 %+1,4 %
Real Estate+0,7 %+4,1 %+0,8 %
Health Care+0,6 %−0,5 %+0,8 %
Consumer Discretionary+0,3 %+8,7 %+0,5 %
Information Technology · THIS SECTOR−0,3 %+6,5 %−0,1 %
Financials−0,3 %−4,5 %−0,1 %
Consumer Staples−1,0 %+3,0 %−0,8 %
Utilities−1,5 %−21,2 %−1,3 %
Industrials−1,7 %−2,3 %−1,6 %
Communication Services———
Developing storylines
No tracked sagas currently linked to DH.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-07-07
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Peers
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated · ServiceNow (NOW)
- EarningsQ2 2026 earnings (expected)2026-08-28 · estimated · Salesforce (CRM)
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Composite score63 / 100
Composite score 0-100 · Data quality 0,60
Data quality0,60 / 1.00
Synthesis
Business
Definitive Healthcare Corp (DH.O) is a software company operating within the Technology sector, specifically providing software and IT services. The firm generates revenue through a subscription model, with key performance indicators including annual recurring revenue and net revenue retention. No specific operating segments or geographic breakdowns are provided in the available data. The company is listed under the ticker DH.O.
Classification92 %
SectorTechnology
Business sectorSoftware & IT Services
IndustrySoftware
AI synthesis
GENERATEDDefinitive Healthcare Corp operates with a capital structure that includes $164.8 million in long-term debt and $163.6 million in cash and equivalents, resulting in a debt-to-equity ratio of 0.59 and a current ratio of 1.64. The company's liquidity position is assessed as medium, with negative net cash after subtracting total debt. The price-to-book ratio of 0.44 and price-to-tangible-book ratio of 0.44 indicate that the company is trading at a significant discount to its book value.
Profitability metrics show a challenging performance, with a return on equity of -49.42% and a return on assets of -18.89%. The company reported a net loss of $138.9 million and an operating loss of $224.8 million, despite generating $241.5 million in revenue. Gross profit of $183.3 million suggests some margin preservation, but the operating margin is negative at -93.0%.
Geographically and segment-wise, the company's exposure is not explicitly detailed in the available data. However, the revenue concentration and segment breakdown are not disclosed, which limits the ability to assess geographic or product diversification. The company's primary business is in healthcare data and analytics, with no disclosed material diversification into other industries.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of $53.8 million contrasts with a free cash flow of -$159.9 million, indicating significant capital expenditures or other cash outflows. The capital expenditure of -$16.7 million suggests some investment in infrastructure, but the overall cash flow position remains constrained.
Risk factors include a medium liquidity risk due to the negative net cash position and a debt-to-equity ratio of 0.59. The dilution risk is assessed as low, with no near-term pressure expected. The company has not disclosed any dilution sources in the available documents, and the dilution potential is not material at this time.
Recent events include analyst price targets ranging from $1.00 to $3.50, with a mean of $2.41 and a median of $2.75. The mean recommendation is 2.58, indicating a mixed outlook with 3 strong-buy ratings and 8 hold ratings. No recent filings or transcripts are provided in the available data to further contextualize these analyst views.
Key takeaways
- Definitive Healthcare Corp is trading at a significant discount to book value, with a price-to-book ratio of 0.44.
- The company is unprofitable, with a return on equity of -49.42% and a net loss of $138.9 million.
- Liquidity is a concern, with negative net cash after subtracting total debt and a debt-to-equity ratio of 0.59.
- Analysts are divided, with a mean price target of $2.41 and a mean recommendation of 2.58.
- The company's growth trajectory is unclear, with no specific revenue growth projections provided.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,86
Market cap
$123.6M
Enterprise valueⓘ
$124.8M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
2.3x
P / Bⓘ
0.4x
P / Tangible bookⓘ
0.4x
Tangible book
$281.1M
Net cashⓘ
-$1.2M
Current ratioⓘ
1.6
Debt / equityⓘ
0.6
ROAⓘ
-18.9%
ROEⓘ
-49.4%
Cash conversionⓘ
-39.0%
CapEx / revenueⓘ
-6.9%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs DH · multiples and returns
MS
MSFT—
MICROSOFT CORPORATION
$388,45
2,90T USDP/E
32,3x
— vs self
Div yield
0,9 %
— vs self
ROE
23,6 %
+73,1 vs self
OR
ORCL—
ORACLE CORPORATION
$188,91
543,3B USDP/E
180,2x
— vs self
Div yield
1,2 %
— vs self
ROE
36,1 %
+85,5 vs self
AD
ADBE—
ADOBE INC.
$219,66
89,3B USDP/E
27,1x
— vs self
Div yield
—
— vs self
ROE
31,3 %
+80,7 vs self
SE
SE—
Sea Ltd
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
NO
NOW—
Servicenow Inc
$100,03
104,0B USDP/E
271,7x
— vs self
Div yield
—
— vs self
ROE
4,0 %
+53,4 vs self
WD
WDAY—
WORKDAY, INC.
$138,46
35,2B USDP/E
168,2x
— vs self
Div yield
—
— vs self
ROE
3,3 %
+52,7 vs self
PA
PANW—
Palo Alto Networks Inc
$359,50
291,6B USDP/E
727,5x
— vs self
Div yield
—
— vs self
ROE
6,2 %
+55,7 vs self
RO
ROP—
Roper Technologies Inc
$360,11
36,9B USDP/E
96,6x
— vs self
Div yield
1,0 %
— vs self
ROE
1,9 %
+51,3 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,17
Predicted surprise
0,00
Beat probability
45 %
Analysts
12
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,17 |
| Revenue | —no estimate | —no estimate | 223,5M USD |
| Operating income | —no estimate | —no estimate | 44,7M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-07-07
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution12 analysts
Strong buy3
Buy0
Hold8
Sell1
Strong sell0
12-month price target$2,41 · Median $2,75
Low $1,00High $3,50
Operating income · consensus44,7M USD
EPS surprise
+43,4 %
reported vs consensus · beat
Revenue surprise
+8,1 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$1,00
Mean$2,41
Median$2,75
High$3,50
Spot$0,86
+181.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-93,1 %Bottom quartile
Net Margin-57,5 %Bottom quartile
ROE-49,4 %Bottom quartile
Capex / Rev-6,9 %Below median
D/E0,59Bottom quartile
Cash Conv-0,39Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Definitive Healthcare Corp Market data — financials · 2026-05-27
- Definitive Healthcare Corp Market data — analyst estimates · 2026-05-27
- Definitive Healthcare Corp Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2024-06-300,00 %$24M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $09 insiders · last 365d
- Director · Class A Common StockOther 189 190 · 2026-06-04
- Director · Class A Common StockOther 189 190 · 2026-06-04
- Director · Class A Common StockOther 189 190 · 2026-06-04
- Director · Class A Common StockOther 189 190 · 2026-06-04
- Chief Financial Officer · Class A Common StockOther 164 377 @ $0,99$163K · 2026-06-01
- Director, Chief Executive Officer · Class A Common StockOther 66 050 @ $0,99$65K · 2026-06-01
- Director, 10% owner, EXECUTIVE CHAIRMAN · Class A Common StockOther 12 166 @ $0,99$12K · 2026-05-01
- Chief Financial Officer · Class A Common StockOther 1 469 @ $0,99$1K · 2026-05-01
- Director, Chief Executive Officer · Class A Common StockOther 37 593 @ $1,09$41K · 2026-04-01
- Director, 10% owner, EXECUTIVE CHAIRMAN · Class A Common StockOther 45 154 @ $1,09$49K · 2026-04-01
- Director, Chief Executive Officer · Class A Common StockOther 175 524 @ $1,28$225K · 2026-03-01
- EVP, Chief Data Officer · Class A Common StockOther 631 068 · 2026-02-24
- Chief Legal Officer · Class A Common StockOther 481 505 · 2026-02-24
- Chief Financial Officer · Class A Common StockOther 733 301 · 2026-02-24
- Director, Chief Executive Officer · Class A Common StockOther 1 735 437 · 2026-02-24
- Director, 10% owner, EXECUTIVE CHAIRMAN · Class A Common StockOther 242 719 · 2026-02-24
- Director, 10% owner, EXECUTIVE CHAIRMAN · Class A Common StockOther 44 545 @ $2,32$103K · 2026-02-01
- Chief Financial Officer · Class A Common StockOther 1 469 @ $2,32$3K · 2026-02-01
- Chief Financial Officer · Class A Common StockOther 195 313 · 2026-01-05
- Director, Chief Executive Officer · Class A Common StockOther 28 236 @ $2,87$81K · 2026-01-01
- EVP, Chief Data Officer · Class A Common StockOther 341 417 @ $2,53$864K · 2025-12-22
- Chief Financial Officer · Class A Common StockOther 1 244 @ $2,77$3K · 2025-11-01
- Director, 10% owner, EXECUTIVE CHAIRMAN · Class A Common StockOther 18 796 @ $2,77$52K · 2025-11-01
- Chief Financial Officer · Class A Common StockOther 8 300 @ $3,56$30K · 2025-10-01
- Director, Chief Executive Officer · Class A Common StockOther 37 593 @ $3,56$134K · 2025-10-01
Short positioning
2.6Mshares short-5.7% vs prior
10.62days to cover
45.3%short of daily vol
2.0Kfails-to-deliver
as of 2026-06-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
DH.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companyPeerSector
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 63.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -7.6%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -4.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -26.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 55.3%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -4.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 66.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 35.5%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -7.2%Derived (calculated)
- Gross margin (FY 2025-12-31): 75.9%Derived (calculated)
- Net margin (FY 2025-12-31): -57.5%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -31.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -18.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -32.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 6.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.64xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 63.3%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 68.4%Derived (calculated)
- Current liabilities (annual): USD 156.79MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- Gross profit (annual): USD 183.28MSEC XBRL filing
- R&D expense (annual): USD 34.78MSEC XBRL filing
- Operating income (annual): USD -224.27MSEC XBRL filing
- Revenue (annual): USD 241.52MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-04 00:00 UTCINSIDER6 insider transactions — 2026-06 · net sell $228k
2026-06-04INSIDERHamood Samuel A transacted 189.2k sh Class A Common Stock — Director
2026-06-04INSIDERStephenson Scott G transacted 189.2k sh Class A Common Stock — Director
2026-06-04INSIDERWinters Kathleen A transacted 189.2k sh Class A Common Stock — Director
2026-06-04INSIDERChilukuri Sastry transacted 189.2k sh Class A Common Stock — Director
2026-06-01INSIDERHeller Casey transacted 164.4k sh Class A Common Stock — Chief Financial Officer ~$163k
2026-06-01INSIDERCoop Kevin transacted 66.0k sh Class A Common Stock — Director, Chief Executive Officer ~$65k
2026-05-01 00:00 UTCINSIDER2 insider transactions — 2026-05
2026-05-01INSIDERKrantz Jason Ronald transacted 12.2k sh Class A Common Stock — Director, 10% owner, EXECUTIVE CHAIRMAN ~$12k
2026-05-01INSIDERHeller Casey transacted 1.5k sh Class A Common Stock — Chief Financial Officer ~$1k
2026-04-01 00:00 UTCINSIDER2 insider transactions — 2026-04
2026-04-01INSIDERCoop Kevin transacted 37.6k sh Class A Common Stock — Director, Chief Executive Officer ~$41k
2026-04-01INSIDERKrantz Jason Ronald transacted 45.2k sh Class A Common Stock — Director, 10% owner, EXECUTIVE CHAIRMAN ~$49k
2026-03-01 00:00 UTCINSIDER1 insider transaction — 2026-03 · net sell $225k
2026-03-01INSIDERCoop Kevin transacted 175.5k sh Class A Common Stock — Director, Chief Executive Officer ~$225k
2026-02-24 00:00 UTCINSIDER7 insider transactions — 2026-02 · net sell $107k
2026-02-24INSIDERGraboske Benjamin transacted 631.1k sh Class A Common Stock — EVP, Chief Data Officer
2026-02-24INSIDERParis Jonathan transacted 481.5k sh Class A Common Stock — Chief Legal Officer
2026-02-24INSIDERHeller Casey transacted 733.3k sh Class A Common Stock — Chief Financial Officer
2026-02-24INSIDERCoop Kevin transacted 1.74M sh Class A Common Stock — Director, Chief Executive Officer
2026-02-24INSIDERKrantz Jason Ronald transacted 242.7k sh Class A Common Stock — Director, 10% owner, EXECUTIVE CHAIRMAN
2026-02-01INSIDERKrantz Jason Ronald transacted 44.5k sh Class A Common Stock — Director, 10% owner, EXECUTIVE CHAIRMAN ~$103k
2026-02-01INSIDERHeller Casey transacted 1.5k sh Class A Common Stock — Chief Financial Officer ~$3k
2026-01-05 00:00 UTCINSIDER2 insider transactions — 2026-01
2026-01-05INSIDERHeller Casey transacted 195.3k sh Class A Common Stock — Chief Financial Officer
2026-01-01INSIDERCoop Kevin transacted 28.2k sh Class A Common Stock — Director, Chief Executive Officer ~$81k
2025-12-22 00:00 UTCINSIDER1 insider transaction — 2025-12 · net sell $864k
2025-12-22INSIDERGraboske Benjamin transacted 341.4k sh Class A Common Stock — EVP, Chief Data Officer ~$864k
Showing the 40 most recent of 47 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-07
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage